StockNews.com Lowers Catalent (NYSE:CTLT) to Sell

Catalent (NYSE:CTLTGet Rating) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other equities analysts have also issued reports on CTLT. Bank of America cut their price objective on shares of Catalent from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, August 30th. Royal Bank of Canada cut their price objective on shares of Catalent from $155.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, August 30th. Morgan Stanley cut their price objective on shares of Catalent from $132.00 to $120.00 and set an “overweight” rating on the stock in a report on Tuesday, August 30th. Jefferies Financial Group cut their price objective on shares of Catalent from $130.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, August 30th. Finally, Stephens cut their price objective on shares of Catalent to $145.00 in a report on Tuesday, September 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.13.

Catalent Stock Performance

Catalent stock opened at $89.94 on Friday. The company has a 50 day moving average price of $102.27 and a 200-day moving average price of $102.57. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.07 and a current ratio of 2.72. Catalent has a fifty-two week low of $86.11 and a fifty-two week high of $142.09. The company has a market capitalization of $16.18 billion, a PE ratio of 31.78, a P/E/G ratio of 1.80 and a beta of 1.36.

Catalent (NYSE:CTLTGet Rating) last posted its quarterly earnings results on Monday, August 29th. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.04. Catalent had a net margin of 10.56% and a return on equity of 14.49%. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the previous year, the firm posted $1.08 earnings per share. The company’s revenue was up 10.5% on a year-over-year basis. As a group, equities analysts forecast that Catalent will post 3.66 earnings per share for the current year.

Insider Activity

In other news, insider Ricky Hopson sold 312 shares of the business’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total transaction of $33,352.80. Following the sale, the insider now directly owns 17,035 shares of the company’s stock, valued at $1,821,041.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Ricky Hopson sold 312 shares of the business’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total transaction of $33,352.80. Following the sale, the insider now directly owns 17,035 shares of the company’s stock, valued at $1,821,041.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Steven L. Fasman sold 4,811 shares of the business’s stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $103.04, for a total transaction of $495,725.44. Following the transaction, the executive vice president now owns 61,853 shares of the company’s stock, valued at $6,373,333.12. The disclosure for this sale can be found here. Insiders have sold 18,018 shares of company stock valued at $1,873,343 over the last ninety days. 0.53% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Leonard Green & Partners L.P. acquired a new position in shares of Catalent in the fourth quarter worth about $616,791,000. Price T Rowe Associates Inc. MD raised its position in shares of Catalent by 9.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 22,303,561 shares of the company’s stock worth $2,392,949,000 after acquiring an additional 2,011,520 shares during the period. Norges Bank acquired a new position in shares of Catalent in the fourth quarter worth about $195,690,000. Novo Holdings A S acquired a new position in shares of Catalent in the first quarter worth about $141,032,000. Finally, Veritas Asset Management LLP raised its position in shares of Catalent by 15.3% in the first quarter. Veritas Asset Management LLP now owns 6,999,686 shares of the company’s stock worth $776,265,000 after acquiring an additional 929,400 shares during the period. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Catalent Company Profile

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Further Reading

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.